• Anagliptin (SK-0403) Vascular Research Workflow

  2026-08-28

  Anagliptin (SK-0403) supports a two-tier workflow that connects DPP-4 target engagement with vascular smooth-muscle physiology. Its value extends beyond glycemic-control models into mechanistic assays of Kv channel modulation and SERCA pump regulation.

• Stat3–NF-κB Synergy in Fyn Neurodegeneration

  2026-08-28

  The 2024 reference study establishes a neural-specific zebrafish model showing that constitutively active Fyn drives dopaminergic neuron loss, mitochondrial aggregation, and microglial inflammation. Transcriptomic and chemical-inhibition experiments identify Stat3 as a downstream Fyn effector that cooperates with NF-κB, providing a mechanistic framework for studying neuroinflammatory neurodegeneration.

• mCherry mRNA for LNP Delivery Assays

  2026-08-27

  EZ Cap™ mCherry mRNA combines Cap 1 capping, 5mCTP and ψUTP modification, and an optimized poly(A) tail for reproducible red reporter expression. It is especially useful for benchmarking lipid nanoparticle delivery, cell localization, and transfection quality before advancing to harder-to-measure therapeutic mRNA or gene-editing payloads.

• Rotigotine Hydrochloride in PD Research

  2026-08-27

  Build reproducible dopaminergic assays with Rotigotine hydrochloride, from SH-SY5Y neuroprotection and cytotoxicity screens to 6-OHDA or MPTP Parkinson’s disease models. Its receptor breadth and translational connection to continuous transdermal delivery make it useful for linking pathway activation with motor, inflammatory, and oxidative-stress readouts.

• Veratridine: A Causal Assay Framework

  2026-08-26

  Veratridine is a voltage-gated sodium channel opener that converts channel gating into a controllable model of depolarization, calcium stress, and excitotoxic injury. This article develops a causal assay framework that distinguishes sodium-channel effects from downstream glutamate and calcium mechanisms.

• Rotigotine Hydrochloride: A Translational Roadmap

  2026-08-26

  A thought-leadership guide to using Rotigotine hydrochloride as a dopamine D2/D3 receptor agonist in Parkinson’s disease research, depression models, and translational dopaminergic signaling studies, with emphasis on receptor breadth, behavioral confounding, delivery strategy, and reproducible experimental design.

• PFOS Injury in HK-2 Cells: Ferroptosis and ER Stress

  2026-08-25

  A 2025 study shows that perfluorooctane sulfonate damages human proximal tubular HK-2 cells alongside ferroptosis-associated iron and lipid peroxidation changes and activation of the endoplasmic reticulum stress response. Its value lies in connecting renal tubular injury with two interacting stress systems, while also defining practical readouts for follow-up mechanistic studies.

• Gallein B7271 for Reliable GPCR Assays

  2026-08-25

  This scenario-driven guide explains how Gallein (SKU B7271), a G protein βγ subunit inhibitor, can be integrated into cell signaling, viability, proliferation, macrophage, and cancer research workflows. It emphasizes solvent controls, model-specific dosing, orthogonal readouts, and practical product-selection criteria supported by formulation and quality-control data.

• Rotigotine Antidepressant Effects in Depression Models

  2026-08-24

  This 2006 study evaluated rotigotine across complementary rat models of anxiety, behavioral despair, learned helplessness, and depression-like hyperactivity. Its main contribution was showing antidepressant-like effects at lower doses while identifying locomotor activation at higher exposure as an important behavioral confound.

• Rotigotine Workflows for Parkinson’s Disease Research

  2026-08-23

  Build reproducible Rotigotine experiments around receptor pharmacology, oxidative-stress readouts, and nose-to-brain formulation comparisons. This practical guide connects SH-SY5Y cell assays with haloperidol-based behavioral models while emphasizing vehicle control, nanoparticle quality, and translational limits.

• Perphenazine Workflows for D2 and Host Defense

  2026-08-22

  Perphenazine combines dopamine D2 receptor antagonism with a broad phenothiazine receptor profile, enabling coordinated neuropharmacology, mitochondrial stress, and host-directed antibacterial studies. This workflow-focused guide shows how to control solvent effects, distinguish receptor biology from cytotoxicity, and translate ROS–autophagy findings into reproducible assays.

• MMAE and Cancer Cell Plasticity

  2026-08-21

  Monomethyl auristatin E (MMAE) is more than a potent cytotoxic reagent: in an antibody-drug conjugate, it can convert tumor-selective recognition into a mechanistically defined mitotic endpoint. This article connects MMAE strategy with evidence on EBV-driven plasticity in nasopharyngeal carcinoma, while distinguishing established findings from translational hypotheses.

• RG7388: Applied MDM2 Antagonist Workflows

  2026-08-20

  RG7388 offers a practical route to reactivate p53 in wild-type p53 cancer models, from biochemical binding assays to oral xenograft studies. This guide connects selective MDM2 inhibition with biomarker-aware chemoradiotherapy experiments, combination testing, and troubleshooting.

• Phenothiazines Strengthen Macrophage Antibacterial Defense

  2026-08-20

  Qiu et al. show that phenothiazines enhance macrophage control of intracellular bacteria by increasing reactive oxygen species, lysosomal activity, and autophagy. The study positions host-directed phenothiazine activity as a mechanistically testable strategy against intracellular infection, while also identifying important limits for translation beyond the infection model.

• VER 155008: HSP 70 Inhibitor Mechanism

  2026-08-19

  VER 155008 is an adenosine-derived HSP 70 inhibitor that targets the ATPase pocket of Hsp70-family chaperones. Product information reports biochemical Hsp70 inhibition at 0.5 μM and cellular growth-inhibition values of 5.3–14.4 μM in selected cancer cell lines, while mouse tumor exposure was limited.

445 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page